SUPN FY 2022 Earnings — Supernus Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena

SUPNSupernus Pharmaceuticals, Inc.

$3B

FY 2022 Earnings

Healthcare Drug Manufacturers - Specialty & Generic

Income Statement

Revenue

$667M+15.1% YoY

Gross Profit

$580M86.9% margin

Operating Income

$46M6.9% margin

Net Income

$61M9.1% margin

EPS (Diluted)

$1.04

Cash Flow

Operating Cash Flow

$117M

Free Cash Flow

$116M

Stock-Based Comp.

$18M

Balance Sheet

Total Assets

$1.7B

Total Liabilities

$816M

Stockholders' Equity

$886M

Cash & Equivalents

$93M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$667M	$580M	+15.1%
Gross Profit	$580M	$505M	+14.9%
Operating Income	$46M	$86M	-46.4%
Net Income	$61M	$53M	+13.6%